MoSHe platform compounds
Preclinical
AmgenMoSHe platform compounds is one of 20 therapeutic programs targeting Muscular Dystrophy. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
28 competitors in Muscular Dystrophy
#DrugCompanyPhaseTrials
1Cialis
Eli LillyApproved
Glucophage
EMD SeronoApproved
Duvyzat
ItalfarmacoPhase 3
Glucocorticoid
AbbViePhase 3
Rayos
RRoxane Laboratories
Phase 2
Emflaza
PPTC Therapeutics
Phase 3
Translarna
PPTC Therapeutics
Phase 2
Bisphosphonate Treatment
UUniversité Catholique de Louvain
Approved
Stem Cell
NNeurogen Brain and Spine Institute
Phase 2
Trehalose
SSeelos Therapeutics, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for MoSHe platform compounds. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company